Progressive Respiratory Failure in Paraneoplastic Pemphigus Associated with Chronic Lymphocytic Leukemia

Dermatology ◽  
2004 ◽  
Vol 208 (3) ◽  
pp. 251-254 ◽  
Author(s):  
M. Brönnimann ◽  
V. von Felbert ◽  
M. Streit ◽  
T. Hunziker ◽  
L.R. Braathen
Keyword(s):  
Respiratory Failure ◽  
Chronic Lymphocytic Leukemia ◽  
Lymphocytic Leukemia ◽  
Paraneoplastic Pemphigus ◽  
Progressive Respiratory Failure

Paraneoplastic Pemphigus in A Patient with Chronic Lymphocytic Leukemia: A Case Report

2018 ◽  
Vol 02 (03) ◽  
pp. 84-88
Author(s):  
Arif Kus ◽  
Abdulkerim Yildiz ◽  
Betul Erdem ◽  
Murat Albayrak ◽  
Cigdem Pala Ozturk ◽  
...  
Keyword(s):  
Case Report ◽  
Chronic Lymphocytic Leukemia ◽  
Lymphocytic Leukemia ◽  
Paraneoplastic Pemphigus

scholarly journals Paraneoplastic pemphigus associated with chronic lymphocytic leukemia: a case report

2018 ◽  
Vol 12 (1) ◽  
Author(s):  
Richard Lucas Konichi-Dias ◽  
Aline Fernanda Ramos ◽  
Mauricio Eiji de Almeida Santos Yamashita ◽  
Cristiane Botelho Miranda Cárcano
Keyword(s):  
Case Report ◽  
Chronic Lymphocytic Leukemia ◽  
Lymphocytic Leukemia ◽  
Paraneoplastic Pemphigus

scholarly journals Could the candidate causal gene (LZTFL1) identified by Oxford University scientists, which doubles the risk of COVID-19-related respiratory failure, be used to boost the Weak immunogenicity of COVID-19 mRNA vaccines in patients with B-cell chronic lymphocytic leukemia (CLL)???. A double edged sward

2021 ◽  
Author(s):  
Mahmoud Ramadan Elkazzaz ◽  
Yousry Esam-Eldin Abo-Amer ◽  
Amr Ahmed ◽  
Tamer Haydara
Keyword(s):  
Respiratory Failure ◽  
Chronic Lymphocytic Leukemia ◽  
B Cell ◽  
Risk Allele ◽  
Lymphocytic Leukemia ◽  
Causal Gene ◽  
Oxford University ◽  
Increased Risk ◽  
University Scientists ◽  
Cell Chronic Lymphocytic Leukemia

Abstract Patients with B-cell chronic lymphocytic leukemia (CLL) have an increased risk of severe infections due to disease- and treatment-related immunodeficiency. As a result, patients with hematologic malignancies have been given priority for primary COVID-19 vaccination. Unfortunately, many studies have suggested that patients with B-cell chronic lymphocytic leukemia (CLL) who have been fully vaccinated can develop severe and often fatal complications. Therefore, adjuvants that can induce mRNA vaccine efficacy are desperately needed for this category of patients with haematological malignancies. A recent, study by Oxford University scientists showed that leucine zipper transcription factor-like 1(LZTFL1), as a candidate causal gene and its enhancer the rs17713054 A risk allele was significantly responsible for the twofold increased risk of respiratory failure from COVID-19 associated with 3p21.31.By using sequence analysis, the risk allele generates a second CCAAT/enhancer binding protein beta (CEBPB) motif in the enhancer. Moreover, neither LZTFL1 variants found in T cells nor B cells are responsible for increasing death risk from COVID-19 infection according to oxford study. Here, we propose attestable hypothesis that trans retinoic acid could enhance the immune response in vaccinated patients with B-cell chronic lymphocytic leukemia (CLL) according to the recent findings of Oxford scientists by inducing the casual gene(LZTFL1) in CD4 T cells and inhibiting (CEBPB) motif.

Concomitant Acute Promyelocytic Leukemia and Chronic Lymphocytic Leukemia: Molecularly Two Distinct Diseases

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 4904-4904 ◽  
Author(s):  
Jingdong Su ◽  
Hazem E. El-Osta ◽  
Reinhold Munker ◽  
Glenn M. Mills ◽  
Srinivas S. Devarakonda
Keyword(s):  
Prostate Cancer ◽  
Bone Marrow ◽  
Respiratory Failure ◽  
Chest Pain ◽  
Chronic Lymphocytic Leukemia ◽  
Acute Promyelocytic Leukemia ◽  
Topoisomerase Ii ◽  
Promyelocytic Leukemia ◽  
Lymphocytic Leukemia ◽  
History Of

Abstract Introduction: Acute myeloid leukemia (AML) developing in chronic lymphocytic leukemia (CLL) patients is very uncommon and is usually treatment-related. Acute promyelocytic leukemia (APL) occurring concurrently with CLL is extremely rare and there is only one published case of treatment-related APL. No case of concomitant APL and CLL in patients without history of malignancy has been found in the literature. We report such a case of coexisting CLL and APL. Case report: A 52-years-old Caucasian male with past medical history of hypertension, diabetes mellitus, and coronary artery disease, presented to an outside facility with chest pain and dyspnea for two day duration. He had lymphocytosis (WBC 31,500 /µL and 66 % lymphocytes) one year prior, however, was lost to follow up and no further workup was pursued. On examination, he was pale with no petechiae or ecchymosis. There was no lymphadenopathy or hepatosplenomegaly. Labs showed WBC 17,000/µL with 97% lymphocytes and 2% blasts, Hemoglobin 6.0 g/dL, and platelet 16,000/µL. Serum troponin was 0.30 ng/mL. EKG revealed ST-depression in lateral leads concerning for non-ST elevation MI (NSTEMI). Patient was admitted and received packed red blood cells and platelet transfusion with resolution of chest pain. Upon transfer to our hospital, he was afebrile and hemodynamically stable. Lab work showed WBC of 72,000/µL and platelet count of 9,000/µL. Slides from outside facility were reviewed and immunohistochemistry from bone marrow specimen revealed dense staining of myeloperoxidase (MPO) on sheets of myeloid blasts and strong CD79a staining on clumps of lymphocytes. Peripheral blood, bone marrow aspiration and biopsy showed two distinct morphological abnormalities including immature myeloid blasts with prominent cytoplasmic granules as well as increased number of small lymphocytes. Flow cytometry demonstrated a clonal B-cell population consistent with chronic lymphocytic leukemia. Further evaluation with fluorescent in-situ hybridization (FISH) revealed presence of a t(15;17) (q22;q12), PML-RARA translocation consistent with acute promyelocytic leukemia. Co-existence of CLL and APL was confirmed. Treatment with All-trans-retinoic acid (ATRA) and hydroxyurea was started immediately along with dexamethasone for prevention of differentiation syndrome. Shortly after initiation of ATRA, patient developed acute hypoxic respiratory failure with extensive patchy opacities in bilateral lungs on chest radiography. WBC further increased to 130,000/µL. Respiratory failure worsened despite bi-level positive airway pressure (BiPAP) and diuretics, and he was subsequently transferred to intensive care unit (ICU). Patient's clinical condition deteriorated rapidly, developed disseminated intravascular coagulation (DIC), and eventually died from cardiopulmonary arrest. Discussion: CLL is the most common hematologic malignancy in adults in western countries and the treatment of CLL is associated with increased incidence of secondary malignancies. However, transformation of CLL into AML is uncommon and most reported cases were therapy-related (t-AML). In patients with t-AML, exposure to topoisomerase II inhibitors (mainly Etoposide), alkylating agents and ionizing radiation are among the main causative factors. AML after treatment with DNA-topoisomerase II inhibitors has a short latency period, presents without a prior myelodysplastic syndrome, and is associated with 11q23 translocation. There was only one reported case of APL which developed 2 years after radiotherapy for prostate cancer in a patient with chronic lymphocytic leukemia. Although no treatment was given for CLL, radiotherapy for prostate cancer in that patient might have contributed to the development of APL, which is considered therapy-related. High dose of radiation has also been considered to increase the risk of t-AML. To date, no report in literature has been found on simultaneous occurrence of CLL and APL in patients without any previous treatment, either for CLL or for other co-existing conditions. We report here the first case of CLL co-existing with APL, diagnosed as two separate disease entities based on evidence from molecular testing and immunohistochemistry staining. APL is a hematological emergency. Management of APL, regardless of it being de novo or therapy-related, is the same. Disclosures No relevant conflicts of interest to declare.

Paraneoplastic pemphigus in a patient with Chronic Lymphocytic Leukemia (CLL)

2015 ◽  
Vol 15 ◽  
pp. S27
Author(s):  
Adan Rios ◽  
Andres Quesada ◽  
Bradley Bowden ◽  
Brian Dihn ◽  
Maren Chan
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Lymphocytic Leukemia ◽  
Paraneoplastic Pemphigus

scholarly journals Paraneoplastic pemphigus with anti-desmocollin 3 autoantibodies and chronic lymphocytic leukemia

2018 ◽  
Vol 35 (1) ◽  
pp. 113-115 ◽  
Author(s):  
Alicja Adaszewska ◽  
Norito Ishii ◽  
Jadwiga Dwilewicz-Trojaczek ◽  
Katarzyna Woźniak ◽  
Takashi Hashimoto ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Lymphocytic Leukemia ◽  
Paraneoplastic Pemphigus

scholarly journals Paraneoplastic Pemphigus: An Indication for Treatment in Chronic Lymphocytic Leukemia

Cureus ◽  
2020 ◽  
Author(s):  
Ifeanyichukwu Onukogu ◽  
Preethi Ramachandran ◽  
Joshua Narh ◽  
Sonu Sahni ◽  
Gardith Joseph
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Lymphocytic Leukemia ◽  
Paraneoplastic Pemphigus ◽  
Indication For Treatment

A novel case of IgA paraneoplastic pemphigus associated with chronic lymphocytic leukemia

2007 ◽  
Vol 56 (5) ◽  
pp. S73-S76 ◽  
Author(s):  
Adam R. Taintor ◽  
Kristin M. Leiferman ◽  
Takashi Hashimoto ◽  
Norito Ishii ◽  
John J. Zone ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Lymphocytic Leukemia ◽  
Paraneoplastic Pemphigus
Sign in / Sign up

Export Citation Format

Share Document